ELIZABETH SHANE, M. D.; DELIA C. BAQUIRAN, M.S.N.; JOHN P. BILEZIKIAN, M.D.
Dichloromethylene diphosphonate (Cl2MDP), an inhibitor of osteoclast function, was evaluated for its ability to lower the serum and urinary calcium in 14 patients with primary hyperparathyroidism. The study was double-blind, placebo-controlled, and cross-over in design. All patients received 12 weeks of Cl2MDP (1600 mg daily) and 12 weeks of placebo in a randomized sequence. The average serum calcium was lowered by Cl2MDP from 11.5 ± 0.1 mg/dL to 10.8 ± 0.2 mg/dL (p < 0.001). In the 3-month follow-up after drug administration, the average serum calcium (11.0 ± 0.2 mg/dL) remained significantly below pretreatment levels (p < 0.01). The reduction in serum calcium was accompanied by a significant decline in the urinary hydroxyproline excretion from 37 ± 3 to 28 ± 2 mg/g creatinine (p < 0.01) and by a 40% reduction in the average urinary calcium excretion from 185 ± 29 to 113± 23 mg/g creatinine (p < 0.01) Administration of Cl2MDP was not associated with any significant changes in parathyroid hormone levels or in urinary cyclic adenosine monophosphate excretion. No side effects were observed. We conclude that Cl2MDP lowers the serum and urinary calcium in patients with primary hyperparathyroidism.
SHANE E, BAQUIRAN DC, BILEZIKIAN JP. Effects of Dichloromethylene Diphosphonate on Serum and Urinary Calcium in Primary Hyperparathyroidism. Ann Intern Med. ;95:23–27. doi: 10.7326/0003-4819-95-1-23
Download citation file:
Published: Ann Intern Med. 1981;95(1):23-27.
Endocrine and Metabolism, Parathyroid Disorders.
Results provided by:
Copyright © 2019 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use